BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37066834)

  • 1. Contrast-enhanced ultrasound liver imaging reporting and data system v2017: patient outcomes after treatment for early-stage hepatocellular carcinoma nodules with category 3-5 and category M.
    Hu YX; Yan CJ; Yun M; Zheng W; Zou XB; Zhang YF; Mao RS; Li LL; Zhou JH
    Br J Radiol; 2023 Jul; 96(1147):20220492. PubMed ID: 37066834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation.
    Min JH; Lee MW; Rhim H; Han S; Song KD; Kang TW; Jeong WK; Cha DI; Kim JM; Choi GS; Kim K
    Eur Radiol; 2024 Jan; 34(1):525-537. PubMed ID: 37526668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Imaging Reporting and Data System: Patient Outcomes for Category 4 and 5 Nodules.
    Choi SH; Byun JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Radiology; 2018 May; 287(2):515-524. PubMed ID: 29457964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
    Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
    Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
    Huang H; Li CQ; He DN; Ruan SM; Li MD; Cheng MQ; Lu MD; Kuang M; Wang W; Wang Y; Chen LD
    Eur Radiol; 2023 Dec; 33(12):9336-9346. PubMed ID: 37405501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
    Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
    Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
    Li L; Zheng W; Wang J; Han J; Guo Z; Hu Y; Li X; Zhou J
    AJR Am J Roentgenol; 2022 Sep; 219(3):434-443. PubMed ID: 35441534
    [No Abstract]   [Full Text] [Related]  

  • 10. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Hepatocellular Carcinoma ≤5 cm: Biological Characteristics and Patient Outcomes.
    Cai WJ; Ying M; Zheng RQ; Liao J; Luo B; Tang L; Cheng W; Yang H; Wei A; Yang Y; Wang H; Luo YC; Liu C; Zhong H; Yang Q; Yu J; Liang P
    Liver Cancer; 2023 Sep; 12(4):356-371. PubMed ID: 37817756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
    Huang Z; Zhou P; Li S; Li K
    Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
    Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
    Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas.
    Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS
    Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.
    Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F
    Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Revision of the LR-M Criteria on the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS.
    Ding J; Qin Z; Zhou Y; Zhou H; Zhang Q; Wang Y; Jing X; Wang F
    Ultrasound Med Biol; 2021 Dec; 47(12):3403-3410. PubMed ID: 34598799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
    Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
    Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
    Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
    Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.